| Clinical data | |
|---|---|
| Other names | beta-Dihydroergocryptine |
| Pregnancy category |
|
| Routes of administration | Oral |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.039.157 |
| Chemical and physical data | |
| Formula | C32H43N5O5 |
| Molar mass | 577.726 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Epicriptine orbeta-dihydroergocryptine is adopamine agonist of theergoline class. It constitutes one third of the mixture known asdihydroergocryptine, the other two thirds consisting ofalpha-dihydroergocryptine. Thealpha differs from thebeta form only in the position of a singlemethyl group, which is a consequence of thebiosynthesis in which theproteinogenic amino acidisoleucine is replaced byleucine.[1]
Thisdrug article relating to thenervous system is astub. You can help Wikipedia byexpanding it. |